Cerebral venous thrombosis in a girl carrier of the prothrombin gene mutation 20210G→A treated by local fibrinolysis of the superior sagittal sinus;Trombosis venosa cerebral en niña portadora de la mutación 20210G→A del gen de la protrombina, tratada mediante fibrinólisis local del seno sagital superior

Revista de Neurologia

Volumn 35, Issue 10, 2002, Pages 913-917

  Pérez Dueñas, Belén ^a,e   Cambra Lasaosa, F J ^a   Noguera Julian A ^a   Palomeque Rico, A ^a   Toll Costa, T ^b   Campistol, J ^c   Guimaraens Martinez L ^a   Vivas Diaz E ^d  

^a Hospital de Barcelona   (Spain)

^b Servicio de Hematologia ^*  (Spain)

^c UNIVERSITY OF BARCELONA   (Spain)

^d HOSPITAL GENERAL DE CATALUNYA   (Spain)

^e Sant Joan de Deu Children's Hospital   (Spain)

Author keywords

Coagulopathy; Paediatrics; Prothrombin G20210A; Stroke; Thrombosis of the venous sinuses; Urokinase

Indexed keywords

ANTICOAGULANT AGENT; HEPARIN; UROKINASE;

ARTICLE; BRAIN ANGIOGRAPHY; CASE REPORT; CHILD; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DROWSINESS; FEMALE; FIBRINOLYSIS; FOCAL EPILEPSY; GENE MUTATION; HEMIPARESIS; HUMAN; LATERAL BRAIN VENTRICLE; MAGNETIC RESONANCE ANGIOGRAPHY; RISK FACTOR; SUPERIOR SAGITTAL SINUS; VEIN THROMBOSIS;

EID: 0037121402     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.3510.2002315     Document Type: Article

References (29)

1. Nuss R, Hays T, Manco-Johnson MJ. Childhood thrombosis. Pediatrics 1995; 96: 291-4.
2. Esnaola-Rojas MM. Diagnóstico y tratamiento de los trastornos de la coagulación. Rev Neurol 1999; 29: 1290-300.
3. Cardo E. Hiperhomocistememia como Factor de Riesgo de ECV en la Infancia. Tesis Doctoral. Barcelona, 2000.
4. Sifontes MT, Nuss R, Jacobson LJ, Griffin JH, Manco-Johnson MJ. Thrombosis in otherwise well children with the factor V Leiden mutation. J Pediatr 1996; 128: 324-8.
5. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3′-untranslated region of the protrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88: 3698-703.
6. De Stefano V, Chiusolo P, Paciaroni K, Casorelli I, Rossi E, Molinari M, et al. Prothrombin G20210A mutant genotype is a risk factor for cerebrovascular ischemic disease in young patients. Blood 1998; 91: 3562-5.
7. Akar N, Akar E, Deda G, Sipahi T, Orsal A. Factor V1691 G→A, prothrombin 20210G→A, and methylentetrahydrofolate reductase 677 C→A variants in Turkish children with cerebral infarct. J Child Neurol 1999; 14: 749-51.
8. Palomeque A. Fibrinolíticos en pediatría. Arch Pediatr 1999; 50: 186-9.
9. Leaker M, Massicotte MP, Brooker L, Andrew M. Thrombolytic therapy in pediatric patients: A comprehensive review of the literature. Thromb Haemost 1996; 76: 132-4.
10. Zenz W, Arlt F, Sodia S, Berghold A. Intracranial hemorrhage during fibrinolytic therapy in children: A review of the literature of the last thirty years. Semin Thromb Haemost 1997; 23: 321-32.
11. Horowitz M, Purdy P, Unwin H, Carstens G, Greenlee R, Hise J, et al. Treatment of dural sinus thrombosis using selective catheterization and urokinase. Ann Neurol 1995; 38: 58-67.
12. Mandel H, Brenner B, Berant M, Rosenberg N, Lanir N, Jakobs C, et al. Coexistence of hereditary homocystinuria and factor V Leiden- effect on thrombosis. N Engl J Med 1996; 334: 763-8.
13. Cardo E, Campistol J, Kirkham F. Papel de la resistencia a la proteína C activada (R-PCA) en el ictus pediátrico. Rev Neurol 1997; 25: 1589-91.
14. Cardo E, Vilaseca MA, Campistol J, Artuch R, Colomé C, Pineda M. Evaluation of hyperhomocysteinaemia in children with stroke. Eur J Paediatr Neurol 1999; 3: 113-7.
15. Cardo E, Campistol J, Caritg J, Ruiz S, Vilaseca MA, Kirkham F. Fatal haemorrhagic infarct in an infant with homocystinuria. Dev Med Child Neurol 1999; 41: 132-5.
16. Rosendaal FR, Doggen CJM, Zivelin A, Arruda VR, Aiach M, Siscovick DS, et al. Geographic distribution of the 20210 G to A prothrombin variant. Thromb Haemost 1998; 79: 706-8.
17. Souto JC, Coll I, Llobet D, del Río E, Oliver A, Mateo J, et al. The prothrombin 20210A allele is the most prevalent genetic risk factor for venous thromboembolism in the Spanish population. Thromb Haemost 1998; 98: 366-9.
18. Rosendaal FR. Risk factors for venous thrombotic disease. Thromb Haemost 1999; 82: 610-9.
19. Streif W, Mitchell LG, Andrew M. Antithrombotic therapy in children. Curr Opin Pediatr 1999; 11: 56-64.
20. Lindmarker P, Schulman S, Sten-Linder M, Wiman B, Egberg N, Johnsson H. The risk of recurrent venous thromboembolism in carriers and non-carriers of the G1691A allele in the coagulation factor v gene and the G20210A allele in the prothrombin gene. Thromb Haemost 1999; 81: 684-9.
21. Einhaupl KM, Villringer A, Meister W. Heparin treatment in sinus venous thrombosis. Lancet 1991; 338: 597-600.
22. Hostalot A, Palomeque A, Pastor X. Terapia fibrinolítica y anticoagulación. Experiencia en pediatría. An Esp Pediatr 1997; 47: 315-8.
23. Palomeque A, Quintillá JM, Mortera C, Mayol J, Castañón M. Repermeabilización de una fistula de Blalock. Otra indicación de fibrinolíticos en pediatría. An Esp Pediatr 1997; (Supl 105): S100.
24. Spearman MP, Jungreis CA, Wehner JJ, Gerszten PC, Welch WC. Endovascular thrombolysis in deep cerebral venous thrombosis. Am J Neuroradiol 1997; 18: 502-6.
25. Holder CHA, Bell DA, Lundell AL, Ulmer JL, Glazier SS. Isolated straight sinus and deep cerebral venous thrombosis: Successful treatment with local infusion of urokinase. J Neurosurg 1997; 86: 704-7.
26. Philips MF, Bagley LJ, Sinson GP, Raps EC, Galetta SL, Zager EL, et al. Endovascular thrombolysis for symptomatic cerebral venous thrombosis. J Neurosurg 1999; 91: 65-71.
27. Genton E, Wolf PS. Urokinase therapy in pulmonary thromboembolism. Am Hearts J 1968; 76: 628.
28. Dukert F, Muller G, Nyman D. Treatment of deep venous thrombosis with streptokinase. Br Med J 1975; 1: 479-81.
29. Cardo E, Pineda M, Vilaseca MA, Artuch R, Campistol J. Factores de riesgo en la enfermedad cerebrovascular infantil. Rev Neurol 2000; 30: 21-7.